Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.12−1.38 (-7.89%)
Close on Nov 13, 2026Market cap $117.10MP/E –Yield –
Cue Biopharma cash
Cash and short-term investments held at the end of each period.
Cue Biopharma's cash was $17.39M at Jun 30, 2026. For fiscal 2025 it was $27.14M, up 20.8% from the year before. The highest annual figure on record is $84.90M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.14M | +20.8% |
| FY2024 | Dec 31, 2024 | $22.46M | -53.7% |
| FY2023 | Dec 31, 2023 | $48.51M | -36.4% |
| FY2022 | Dec 31, 2022 | $76.29M | +18.5% |
| FY2021 | Dec 31, 2021 | $64.40M | -24.1% |
| FY2020 | Dec 31, 2020 | $84.90M | +42.9% |
| FY2019 | Dec 31, 2019 | $59.41M | +51.5% |
| FY2018 | Dec 31, 2018 | $39.21M | -38.3% |
| FY2017 | Dec 31, 2017 | $63.53M | +325.7% |
| FY2016 | Dec 31, 2016 | $14.93M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.39M | -36.7% |
| Q1 FY2026 | Mar 31, 2026 | $16.38M | +24.7% |
| Q4 FY2025 | Dec 31, 2025 | $27.14M | +20.8% |
| Q3 FY2025 | Sep 30, 2025 | $18.67M | -42.4% |
| Q2 FY2025 | Jun 30, 2025 | $27.49M | -8.4% |
| Q1 FY2025 | Mar 31, 2025 | $13.14M | -68.0% |
| Q4 FY2024 | Dec 31, 2024 | $22.46M | -53.7% |
| Q3 FY2024 | Sep 30, 2024 | $32.42M | -40.7% |
| Q2 FY2024 | Jun 30, 2024 | $30.03M | -48.1% |
| Q1 FY2024 | Mar 31, 2024 | $41.03M | -38.0% |
| Q4 FY2023 | Dec 31, 2023 | $48.51M | -36.4% |
| Q3 FY2023 | Sep 30, 2023 | $54.69M | -7.6% |
| Q2 FY2023 | Jun 30, 2023 | $57.89M | -12.5% |
| Q1 FY2023 | Mar 31, 2023 | $66.20M | -2.5% |
| Q4 FY2022 | Dec 31, 2022 | $76.29M | +18.5% |
| Q3 FY2022 | Sep 30, 2022 | $59.18M | -12.5% |
| Q2 FY2022 | Jun 30, 2022 | $66.13M | -10.5% |
| Q1 FY2022 | Mar 31, 2022 | $67.93M | -7.3% |
| Q4 FY2021 | Dec 31, 2021 | $64.40M | -24.1% |
| Q3 FY2021 | Sep 30, 2021 | $67.63M | -26.3% |
| Q2 FY2021 | Jun 30, 2021 | $73.92M | -13.0% |
| Q1 FY2021 | Mar 31, 2021 | $73.26M | +50.3% |
| Q4 FY2020 | Dec 31, 2020 | $84.90M | +42.9% |
| Q3 FY2020 | Sep 30, 2020 | $91.80M | +192.6% |
| Q2 FY2020 | Jun 30, 2020 | $84.93M | +200.6% |
| Q1 FY2020 | Mar 31, 2020 | $48.73M | +57.8% |
| Q4 FY2019 | Dec 31, 2019 | $59.41M | +51.5% |
| Q3 FY2019 | Sep 30, 2019 | $31.38M | -19.9% |
| Q2 FY2019 | Jun 30, 2019 | $28.26M | -38.2% |
| Q1 FY2019 | Mar 31, 2019 | $30.88M | -41.8% |
| Q4 FY2018 | Dec 31, 2018 | $39.21M | -38.3% |
| Q3 FY2018 | Sep 30, 2018 | $39.18M | +1052.4% |
| Q2 FY2018 | Jun 30, 2018 | $45.74M | +525.9% |
| Q1 FY2018 | Mar 31, 2018 | $53.10M | +386.9% |
| Q4 FY2017 | Dec 31, 2017 | $63.53M | +325.7% |
| Q3 FY2017 | Sep 30, 2017 | $3.40M | – |
| Q2 FY2017 | Jun 30, 2017 | $7.31M | – |
| Q1 FY2017 | Mar 31, 2017 | $10.91M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.93M | – |
See a number that looks wrong?